Equity Overview
Price & Market Data
Price: $6.75
Daily Change: +$0.05 / 0.74%
Daily Range: $6.45 - $6.77
Market Cap: $1,402,229,888
Daily Volume: 613,722
Performance Metrics
1 Week: 8.87%
1 Month: 2.58%
3 Months: 61.48%
6 Months: 47.38%
1 Year: 146.4%
YTD: 45.16%
Company Details
Employees: 119
Sector: Health technology
Industry: Biotechnology
Country:
Details
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.